The Division of Molecular Medicine and Gene Therapy is located at the Biomedical Center (BMC), Lund University, Sweden. Established as a joint venture between the Medical Faculty at Lund University and the Hematology Clinic at Lund University Hospital, our mission is to translate basic science to clinical applications.
Our research focuses on hematopoiesis, the continuous and dynamic process of blood cell formation. The laboratory consists of eight closely collaborating research groups that all share a common interest in investigating the properties of blood stem cells to eventually understand and treat hematological disorders.
Five of our researchers belong to the Hemato-Linné Excellence Linnaeus Research Environment funded by The Swedish Research Council and Lund University. Several of the groups are engaged in StemTherapy, a Strategic Research Area for Stem Cells and Regenerative Medicine that is also supported by The Swedish Research Council.
Please welcome Hooi Min Tan Grahn! Hooi Min joined the Karlsson group from the Joslin Diabetes Center, affiliated Harvard Medical School, Boston, and will be embedded in the Wallenberg project. The aim of the project is to understand the rules for how the stem cell compartment is organized to sustain regeneration throughout life.
Congratulations to Mattias Magnusson, Kenichi Miharada, and Sofie Singbrant Söderberg, who altogether were awarded grants worth 4.2 million SEK.
Kenichi Miharada and Mattias Magnusson received 2 million SEK each from the Kamprad Family Foundation for their work on cancer-related anemia and individualised cancer treatment, respectively. Sofie Singbrant Söderberg was awarded 200.000 SEK project support from the Clas Groschinsky Foundation for identifying novel mechanisms to treat MDS-related refractory anemia.
The Division of Molecular Medicine and Gene Therapy turns 20 years and we therefore take pleasure in announcing a symposium in honor of Stefan Karlsson. Stefan founded the Division in 1995 and has since then been the driving force in establishing the strong hematopoiesis environment at Lund University.
Venue: Belfrage Lecture hall, BMC D15, Klinikgatan 32
Date and time: May 15th at 13.00 - 16.30
Congratulations to Johan Flygare, who was awarded funding from The Diamond Blackfan Anemia Foundation (DBAF) and Diamond Blackfan Anemia Canada (DBAC) to continue his research on the development of safer and more potent drugs to treat DBA. Using a chemical screen of 12,000 substances, Dr. Flygare and his team have identified several potential drug targets that showed a therapeutic effect on the formation of red blood cells. They will now focus their efforts on the characterisation of these novel compounds and their therapeutic mechanisms.
Professor Ross Hannan from John Curtin School of Medical Research, Australian National University, Canberra, Australia, will be visiting Lund on May 7-8. He will give a lecture entitled: ”Nucleolar stress: A paradigm that underlies hematologic disease” on Thursday May 7 at 14:00 in Segerfalk lecture hall, BMC A10.
This seminar is sponsored by StemTherapy.